Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?

Keunhee Kang; Ji H.oon Kim

doi:10.4166/kjg.2014.63.5.329

Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?

Keunhee Kang, Ji H.oon Kim

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	329-332
Number of pages	4
Journal	The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume	63
Issue number	5
DOIs	https://doi.org/10.4166/kjg.2014.63.5.329
Publication status	Published - 2014 May 1

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4166/kjg.2014.63.5.329

Cite this

@article{558cf5efb0ff4b2a87f7f8492c10415f,

title = "Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?",

author = "Keunhee Kang and Kim, {Ji H.oon}",

year = "2014",

month = may,

day = "1",

doi = "10.4166/kjg.2014.63.5.329",

language = "English",

volume = "63",

pages = "329--332",

journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",

issn = "1598-9992",